Phaseline

Targets › WISP1

WISP1 (CCN family member 4): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Respiratory; next expected readout Aug 2027.

Downstream regulator in the Wnt/Frizzled-signaling pathway. Associated with cell survival. (UniProt, O95388)

Open in Phaseline: the race on WISP1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Mediar TherapeuticsMTX-463
IgG1 monoclonal antibody directed against WNT-inducible signaling pathway protein 1 (WISP1
WISP1Phase 2Idiopathic Pulmonary FibrosisAug 2027

Conditions

Idiopathic Pulmonary Fibrosis (1)

Modalities

protein or peptide (1)

Companies

Mediar Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.